TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

Exclusion Criteria

• •1. Primary CNS malignancy or uncontrolled CNS metastases.
• •2. Other malignancies within 5 years (except adequately treated non-melanoma skin cancer or carcinoma in situ).
• •3. Active autoimmune disease or history of autoimmune disease.
• •4. Immunodeficiency, including HIV positivity.
• •5. Bleeding disorders (inherited or acquired).
• •6. Clinically significant cardiovascular disease.
• •7. Active infection (including tuberculosis, hepatitis B/C, syphilis).
• •8. Pregnant or breastfeeding women.
• •9. Clinically significant ascites . 10 Uncontrolled pleural effusion or pericardial effusion.
• •11\. Prior cell or gene therapy. 12. Severe drug hypersensitivity history. 13. Investigator-assessed unsuitability for trial participation.